Researchers have documented the innovative application of non-autologous exosomes for the delivery of CRISPR/Cas9 plasmid DNA, specifically aimed at targeting the mutant Kras G12D oncogenic allele within pancreatic cancer cells. Here, KRAS is linked to pancreatic neoplasm.